Literature DB >> 8496395

Effect of beta propiolactone on specific antibody measurements by ELISA.

A E Agbarakwe1, S A Misbah, H Griffiths, H M Chapel.   

Abstract

Serum samples from 30 HIV seronegative patients were treated with beta propiolactone (BPL) to determine whether BPL interfaces with ELISA for specific antibodies against protein and carbohydrate antigens. BPL had no discernible effect on specific antibody measurements by ELISA. With the measuring need for specific antibody measurements in the management of HIV seropositive patients, it is reassuring that this laboratory safety measure does not impair the reliability of results.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8496395      PMCID： PMC501222          DOI： 10.1136/jcp.46.4.368

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  8 in total

1.  Investigations of the use of beta-propiolactone in virus inactivation.

Authors:  G A LOGRIPPO
Journal:  Ann N Y Acad Sci       Date:  1960-01-13       Impact factor: 5.691

2.  Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule.

Authors:  R Booy; S A Taylor; S R Dobson; D Isaacs; G Sleight; S Aitken; H Griffiths; H Chapel; R T Mayon-White; J A Macfarlane
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

3.  ELISA determination of IgG antibodies to pneumococcal capsular polysaccharides in a group of children.

Authors:  K P Windebank; J A Faux; H M Chapel
Journal:  J Immunol Methods       Date:  1987-11-23       Impact factor: 2.303

4.  Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection.

Authors:  M C Steinhoff; B S Auerbach; K E Nelson; D Vlahov; R L Becker; N M Graham; D H Schwartz; A H Lucas; R E Chaisson
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

Review 5.  Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives.

Authors:  E N Janoff; R F Breiman; C L Daley; P C Hopewell
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

6.  Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine.

Authors:  M C Rodriguez-Barradas; D M Musher; C Lahart; C Lacke; J Groover; D Watson; R Baughn; T Cate; G Crofoot
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

7.  Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.

Authors:  R Booy; S J Aitken; S Taylor; G Tudor-Williams; J A Macfarlane; E R Moxon; L A Ashworth; R T Mayon-White; H Griffiths; H M Chapel
Journal:  Lancet       Date:  1992-02-29       Impact factor: 79.321

8.  Effect of beta-propiolactone--an inhibitor of HTLV III/LAV activity--on immunological analyses.

Authors:  M J Ball; V Spriggs; P M Sutton; H Chapel
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.